



Synlogic to Present at the 34th Annual J.P. Morgan Healthcare Conference

January 5, 2016

CAMBRIDGE, Mass., – January 5, 2016 – Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced that J.C. Gutiérrez-Ramos, Ph.D., Chief Executive Officer of Synlogic will present at a company overview session at the 34th Annual J.P. Morgan Healthcare Conference.

Dr. Gutiérrez-Ramos will focus on a new class of therapeutics that Synlogic is pioneering based on its innovative synthetic biotics drug discovery and development platform. Dr. Gutiérrez-Ramos will also discuss the Company's robust pipeline of candidate medicines for the potential treatment of rare genetic metabolic diseases and the broad application of the synthetic biotics platform to treat other serious diseases, including inflammatory, metabolic and cardiovascular.

Synlogic's presentation will take place on January 12, 2016 at 1:30p.m. PT (4:30p.m. ET) in the Elizabethan C Room at the Westin St. Francis Hotel in San Francisco.

About Synthetic Biotics

Synthetic biotics are a new class of medicines designed from natural probiotic bacteria that are engineered using Synlogic's proprietary synthetic biology and microbiome platform to treat disease. Synthetic biotics operate from the microbiome and perform specific metabolic transformations to correct disease-causing metabolic dysregulation throughout the body. This innovative approach to disease correction allows the shifting of a corrected and enhanced metabolic function from a disease organ to a stable, non-colonizing fraction of the microbiome.

About Synlogic

Synlogic is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, pioneering the development of a novel class of therapeutics, called synthetic biotics, based on its proprietary synthetic biology and microbiome platform. Synlogic's two lead therapeutic programs are being developed for the potential treatment of rare inborn errors of metabolism of Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition to the company's proprietary pipeline focused on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. Synlogic is backed by leading life sciences investors, including Atlas Venture, New Enterprise Associates (NEA) and the Bill & Melinda Gates Foundation. For more information, please visit <http://synlogictx.com/>.

CONTACT:

Synlogic
Alison Silva
Chief Operating Officer
617-299-8404

Kathryn Morris (Media)
The Yates Network
845-635-9828